- Details
- Andrea Miyahira interviews Abhijit Parolia about his group's study on NSD2's role in prostate cancer. Dr. Parolia explains how NSD2, a histone methyltransferase, reprograms androgen receptor (AR) activity in prostate cancer cells. The research reveals that NSD2 is upregulated in malignant prostate tissue and is crucial for AR binding to chimeric AR-FOXA1 sites, promoting tumor growth. Using CRISPR...
|
- Details
- Andrea Miyahira interviews Cornelia (Chien-Kuang) Ding about her study on predicting prostate cancer grade reclassification using a deep learning-based grading algorithm. Dr. Ding discusses their evaluation of the AIRAProstate algorithm across two cohorts at Johns Hopkins University. The study reveals that AI-based upgrading of initial biopsies is associated with later grade reclassification in ac...
|
- Details
- Andrea Miyahira interviews Michael Haffner about his group's study on the expression of TROP2, CEACAM5, and DLL3 in metastatic prostate cancer, published in NEJM Evidence. Dr. Haffner discusses their analysis of over 750 samples from 52 patients in a rapid autopsy cohort, examining protein expression across different molecular subtypes of castration-resistant prostate cancer. The study reveals dis...
|
- Details
- Alexandra Sokolova discusses her team's study on genomic alterations influencing the response to lutetium-177 PSMA in metastatic castration-resistant prostate cancer. Their research highlights the need for better biomarkers to predict patient outcomes with lutetium-177 PSMA, as not all patients respond to this treatment. Utilizing data from a collaborative database of over 2000 patients, Dr. Sokol...
|
- Details
- Tanya Dorff discusses her team's Phase 1 trial on PSCA CAR T cell therapy for metastatic castration-resistant prostate cancer, published in Nature Medicine. Dr. Dorff highlights that prostate cancer's immunosuppressive environment poses significant challenges, making the development of potent therapies like CAR T cells crucial. The trial involved administering CAR T cells, initially without and th...
|
- Details
- Andrea Miyahira talks with Hiba Khan about her presentation on germline genetic associations in prostate cancer. Dr. Khan's study, leveraging data from Invitae, explores genetic testing results linked to medical records to identify gene-specific associations and potential disparities in testing among diverse populations. Key findings reveal that BRCA2 is the most common mutation across all demogra...
|
- Details
- Edmond Kwan discusses his latest research on circulating tumor DNA (ctDNA) as a predictive marker for response to Lutetium PSMA-617 versus cabazitaxel. The Phase II TheraP trial compared these treatments in patients with advanced metastatic castration-resistant prostate cancer, utilizing dual imaging selection. Dr. Kwan highlights that ctDNA fraction, the proportion of tumor-derived DNA in circula...
|
- Details
- Andrea Miyahira speaks with Catherine Nam about her paper, "The Future is Female: Urology Workforce Projection from 2020 to 2057," published in Urologic Clinics of North America. Dr. Nam addresses the critical issue of the urologic workforce shortage, driven by factors like aging practitioners and limited residency slots due to the Balanced Budget Act of 1997. As the demand for urologic care is se...
|
- Details
- Ping Mu discusses his team's paper, "ZNF397 Deficiency Triggers TET2-Driven Lineage Plasticity in AR-Targeted Therapy Resistance in Prostate Cancer," published in Cancer Discovery. Dr. Mu explains that while primary prostate cancer can be managed effectively, resistance to androgen receptor (AR)-targeted therapies in metastatic cases remains a significant challenge. His research identifies the zin...
|
- Details
- Andrea Miyahira interviews Estefania Labanca about her team's work, featured in the paper "Integrative Molecular Analyses of the MD Anderson Prostate Cancer Patient-Derived Xenograft Series." Dr. Labanca highlights the MD Anderson Prostate Cancer Patient-Derived Xenograft (MDA PCa PDX) Program, a pioneering effort started over 30 years ago by Dr. Navone to model lethal prostate cancer, especially...
|
